AOD-9604 research guide

AOD-9604 in Empalme — Fat Loss Peptide Research Guide

AOD-9604 research guide for Empalme. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

Research-Grade AOD-9604 for Empalme Investigators

For anyone in Empalme searching for AOD-9604, the key fact to understand is that this compound moves through online research channels. What this means for Empalme researchers is that your location matters far less than your ability to verify analytical documentation — and those verification methods are accessible to anyone. A properly operating AOD-9604 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. The sections below cover what Empalme researchers need to know about purchasing, testing, and working with AOD-9604 for research purposes.

AOD-9604: What the Research Shows

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Empalme comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.

How to Source AOD-9604 — Vendor Guide

Before looking at individual vendors, build a clear picture of what a proper COA looks like — so you can identify whether a supplier meets the standard. A COA for AOD-9604 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. Community reputation in research forums is a useful additional signal to COA verification — vendors with multi-year positive track records have proved themselves through consistent results. For Empalme researchers making a first AOD-9604 purchase: verify the vendor against this framework, start with a modest quantity, and confirm the COA batch number matches your received product before use.

Order AOD-9604 — ships to Empalme
COA-verified · International tracking · Research grade
Order Now →

Safe Research Practices for AOD-9604

AOD-9604 operates outside approved pharmaceutical regulation — researchers should understand that the risk characterisation for this compound is based on preclinical evidence rather than regulated clinical data. Proper handling of AOD-9604 requires careful sterile procedure — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and cold chain maintenance from receipt through use. Bacterial endotoxin contamination is the greatest safety hazard unique to this class of compound — verify endotoxin testing is documented in your batch COA before any injectable research application. Protocol documentation — documenting product details, dates, and administration precisely — is a research best practice for AOD-9604 that ensures unusual findings can be explained.

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →